Valuation: Compass Therapeutics, Inc.

Market Cap 349M 307M 287M 263M 492M 33.46B 504M 3.4B 1.33B 16.56B 1.31B 1.28B 57.25B P/E 2026 *
-4.45x
P/E 2027 * -4.18x
Enterprise Value 199M 175M 164M 150M 281M 19.1B 288M 1.94B 758M 9.45B 749M 732M 32.67B EV / Sales 2026 *
-96.9x
EV / Sales 2027 * 8.6x
Free-Float
87.55%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 65 27/05/2024
Director of Finance/CFO 54 08/12/2024
Chief Tech/Sci/R&D Officer 50 31/12/2025
Director TitleAgeSince
Director/Board Member 65 31/12/2013
Director/Board Member 64 31/12/2014
Chairman 61 31/12/2014
Change 5-day change 1-year change 3-year change Capi.($)
-10.80%+32.67% - - 349M
-3.33%-5.82%+43.46%+64.25% 55.2B
+2.83%+0.48%+28.18%+82.59% 55.6B
+0.54%+1.22%-16.62%-13.47% 23.51B
-0.97%-3.30%-1.79%+383.00% 22.35B
-4.01%-3.67%+13.17%-14.29% 20.6B
-1.82%-3.91%+25.01%-34.36% 17.45B
-3.34%-7.77%+23.78%+536.66% 15.16B
-2.09%+0.64%+49.78%+178.74% 13.91B
-3.14%-8.47%+165.37%+292.18% 13.74B
Average -2.60%-1.27%+36.70%+163.92% 26.39B
Weighted average by Cap. -1.14%-0.52%+31.86%+126.84%

Financials

2026 *2027 *
Net sales -2.06M -1.81M -1.69M -1.55M -2.9M -197M -2.97M -20.01M -7.82M -97.5M -7.72M -7.56M -337M 25.27M 22.2M 20.73M 19.02M 35.61M 2.42B 36.48M 246M 96.11M 1.2B 94.87M 92.81M 4.14B
Net income -82.44M -72.44M -67.61M -62.05M -116M -7.9B -119M -802M -314M -3.91B -310M -303M -13.51B -89.57M -78.7M -73.46M -67.42M -126M -8.58B -129M -871M -341M -4.25B -336M -329M -14.68B
Net Debt -150M -132M -123M -113M -211M -14.37B -217M -1.46B -571M -7.11B -563M -551M -24.58B -132M -116M -108M -99.36M -186M -12.64B -191M -1.28B -502M -6.26B -496M -485M -21.63B
Logo Compass Therapeutics, Inc.
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
1.940USD
Average target price
8.500USD
Spread / Average Target
+338.14%

Quarterly revenue - Rate of surprise